https://www.jnj.com/media-center/press-releases/janssen-announces-u-s-fda-approval-of-cabenuva-rilpivirine-and-cabotegravir-the-first-long-acting-regimen-for-the-treatment-of-hiv
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First...
Jul 17, 2025 - CABENUVA offers adults living with HIV a new once-monthly injectable option for maintaining viral suppression